The latest update on Curis centers on a refreshed price target that holds fair value at US$14.00 while reshaping the story ...

Shares of Curis Inc (NASDAQ:CRIS) surged around 19% in premarket trading on Wednesday after the biotech group said it has ...

LEXINGTON, Mass., Oct. 21, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today highlighted ...

On January 7, 2026, Curis entered into a private placement securities purchase agreement with healthcare-focused institutional investors and company insiders for a PIPE financing structured around 20, ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, ...

The list of biotechs under clinical hold keeps getting longer. Curis is the latest company to join the list, with the FDA slapping a partial hold on a phase 1/2a leukemia study while it gathers ...

LEXINGTON, Mass., Oct. 29, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule ...

A Curis clinical trial under a partial FDA hold for more than a year is now cleared to resume, and the biotech is working with clinical sites to enroll patients whose blood cancers exhibits certain ...

What a difference a day makes. Following a serious pop for its stock on Wednesday, given very encouraging news about one of its pipeline drugs, Curis (NASDAQ: CRIS) saw its shares dive by almost 20% ...

Cancer drug specialist Curis (NASDAQ: CRIS) had a Friday to forget. The biotech's share price took a nearly 37% hit after the company reported some disquieting news about a leading pipeline drug.